TrialThe oncologist2025

Less frequent intravenous dosing of nemvaleukin alfa in patients with advanced solid tumors: the phase 1/2 ARTISTRY-3 trial.

Sarina A Piha-Paul et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.